Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1

Abstract Background Oncolytic viruses preferentially replicate in tumors as compared to normal tissue and promote immunogenic cell death and induction of host systemic anti-tumor immunity. HSV-1 was chosen for further development as an oncolytic immunotherapy in this study as it is highly lytic, inf...

Full description

Bibliographic Details
Main Authors: Suzanne Thomas, Linta Kuncheria, Victoria Roulstone, Joan N. Kyula, David Mansfield, Praveen K. Bommareddy, Henry Smith, Howard L. Kaufman, Kevin J. Harrington, Robert S. Coffin
Format: Article
Language:English
Published: BMJ Publishing Group 2019-08-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Oncolytic viruses
Herpes simplex-1
Immunotherapy
Anenestic effect
Online Access:http://link.springer.com/article/10.1186/s40425-019-0682-1

Internet

http://link.springer.com/article/10.1186/s40425-019-0682-1

Similar Items